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Immunosuppressive factors, such as soluble major histocompatibility complex class I 
chain-related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1), are 
involved in tumor immune escape mechanisms (TIEMs) exhibited by head and neck 
squamous cell carcinomas (HNSCCs) and may represent opportunities for therapeutic 
intervention. In order to overcome TIEMs, we investigated the antibody-dependent cel-
lular cytotoxicity (ADCC), cytokine release and retargeted tumor infiltration of sMICA-in-
hibited patient NK cells expressing Fcγ receptor IIIa (FcγRIIIa, CD16a) in the presence 
of cetuximab, an anti-epidermal growth factor receptor (HER1) monoclonal antibody 
(mAb). Compared to healthy controls, relapsed HNSCC patients (n = 5), not currently in 
treatment revealed decreased levels of circulating regulatory NK cell subsets in relation to 
increased cytotoxic NK cell subpopulations. Elevated sMICA and TGF-β1 plasma levels 
correlated with diminished TNFα and IFN-γ release and decreased NKG2D (natural killer 
group 2 member D)-dependent killing of HNSCC cells by NK cells. Incubation of IL-2-
activated patient NK cells with patient plasma containing elevated sMICA or sMICA ana-
logs (shed MICA and recombinant MICA) significantly impaired NKG2D-mediated killing 
by down-regulation of NKG2D surface expression. Of note, CD16 surface expression 
levels, pro-apoptotic and activation markers, and viability of patient and healthy donor 
NK cell subpopulations were not affected by this treatment. Accordingly, cetuximab 
restored killing activity of sMICA-inhibited patient NK cells against cetuximab-coated 
primary HNSCC cells via ADCC in a dose-dependent manner. Rapid reconstitution of 
anti-tumor recognition and enhanced tumor infiltration of treated NK cells was monitored 
by 24 h co-incubation of HNSCC tumor spheroids with cetuximab (1 μg/ml) and was 
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inTrODUcTiOn
Natural killer cells are lymphoid effector cells important for the 
innate immune response against virally infected and malignant 
cells (1, 2). NK cells eliminate transformed target cells during 
cytotoxic interactions by releasing pro-inflammatory cytokines, 
especially IFN-γ and TNF-α (3). Similarly, tumor-infiltrating NK 
cells can trigger stimulating interactions via “cell cross-talk” with 
dendritic cells (DCs), possibly facilitating tumor antigen presen-
tation and induction of tumor antigen-directed T-cell responses. 
This demonstrates the constitutive role of NK cells as mediators 
between the innate and acquired immune systems (4–6). In this 
respect, NK cell killing activity is regulated by both stimulatory 
and inhibitory receptors. Interaction between NK cell inhibitory 
receptors in the presence or absence of MHC class I molecules 
on normal and possible target cells was described as the “missing 
self ” hypothesis (7, 8). Activating receptors include the natural 
cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46 with 
poorly characterized ligands, and the NKG2D receptor, which 
recognizes a variety of well-defined ligands expressed by trans-
formed cells (9–12). Several studies confirmed the predominant 
relevance of NKG2D in efficient recognition and elimination of 
tumor- and “stressed” cells by targeted binding of MICA and 
MICB (9, 10, 12). Interestingly, elevated levels of soluble forms of 
these NKG2D ligands (sMICA and sMICB), generated by matrix 
metalloproteinase (MMP)-dependent proteolytic cleavage 
(“shedding”) were detected in plasma/serum of cancer patients 
(13). These soluble NKG2D ligands are responsible for systemic 
reduction of NKG2D expression on the surface of various circulat-
ing blood lymphocytes, especially cytotoxic NK cells, NK-like T 
(NKT) cells, and CD8+ αβ+- and γδ+-T cells. Thus, these immune 
modulating effects resulted in decreased tumor surveillance by 
attenuated recognition and elimination of malignant cancer cells 
(14–16).
Some reports described NK cell dysfunction in patients with 
head and neck squamous cell carcinoma (HNSCC). These highly 
aggressive solid tumors originate from the epithelial lining of the 
upper aero-digestive tract and are able to escape NK cell-mediated 
immunosurveillance. Tumor progression is accomplished by 
significantly reduced expression levels of NKG2D on effector 
cells (17–20). Detection of increased sMICA plasma levels moni-
tored in HNSCC patients at advanced disease stages (stage IV) 
and poor clinical prognosis further supports the importance of 
diminished tumor surveillance in HNSCC progression (21, 22). 
Indeed, high sMICA levels coincide with increased frequencies 
of lymph node (LN) metastasis. Additionally, decreased survival 
rates in high-risk cancer patients are potentiated by high sMICB 
levels (19, 20, 23). Interestingly, the multiple dysfunctions of NK 
cells can be largely reversed by cancer antigen-targeted antibod-
ies, which stimulate the antibody-dependent cellular cytotoxicity 
(ADCC)-mediated cytotoxicity of activated NK cells to selec-
tively eliminate malignant cells. Therefore, multiple monoclonal 
antibodies (mAbs) have been designed to target diverse tumor 
surface molecules. Based on the assumption that mAbs interact 
specifically with tumor target molecules, mAbs could affect tumor 
cells by directly inhibiting essential signaling pathways initiated 
by target molecules and/or by stimulating effector cell cytotox-
icity, resulting in tumor elimination. One highly investigated 
cancer antigen for treatment of solid tumors is the epidermal 
growth factor receptor (EGFR). EGFR is a member of the ErbB 
protein family, which consists of four transmembrane receptor 
proteins, including HER1 [EGFR, ErbB1: avian erythroblastic 
leukemia viral (v-erb-b) oncogene homolog, receptor for EGF], 
HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4) (24–26). 
EGFR overexpression is associated with poor clinical prognosis 
in multiple solid tumors and EGFR signaling plays an important 
role in malignant cell migration, evasion, and proliferation (27). 
Therefore, mAbs designed to target EGFR were developed. In the 
last decade, cetuximab, an anti-EGFR human-mouse chimeric 
IgG1 monoclonal antibody (mAb) was approved by the Food 
and Drug Administration (FDA) for treatment of metastatic 
colorectal cancer, metastatic non-small cell lung cancer, and 
HNSCC patients (28, 29). However, only a weak to moderate 
(10–20%) benefit was observed in clinical trials with high-risk 
cancer patients (30–35). In this context, HNSCC cells may have 
evaded NK cell immunosurveillance due to polymorphisms in the 
FcγRIIIa (CD16a) on effector cells that impact interaction with 
the IgG1 Fc, heavy-chain, portion of cetuximab. This partially elu-
cidates patient-specific responses to cetuximab and underscores 
the essential importance of modulating immunological synapses 
(36–38). In addition, the tumor microenvironment can impact 
lymphocyte-dependent immunosurveillance, which correlated 
strongly with tumor infiltration as well as NK cell-mediated kill-
ing activity. The ability to control these factors could contribute 
to improved prognosis in some malignant diseases (39–42). Thus, 
NK cells as key players in ADCC-related cetuximab activity were 
able to infiltrate primary colorectal adenocarcinomas and NK 
cell infiltration was an independent predictor for response and 
progression-free survival in patients receiving cetuximab treat-
ment (43).
Recently, we described a decreased anti-tumor recognition, 
cytokine release and a reduced NKG2D expression on NK cells 
from untreated HNSCC patients. In vitro blocking experiments 
revealed a synergistic negative effect of sMICA potentiated by 
TGF-β1 on the killing activity of patient NK cells (22). In the 
current study, cetuximab treatment reconstituted the tumor 
characterized by increased IFN-γ and TNFα secretion. This data show that the impaired 
NK cell-dependent tumor surveillance in relapsed HNSCC patients could be reversed 
by the re-establishment of ADCC-mediated effector cell activity, thus supporting NK 
cell-based immunotherapy in combination with antineoplastic monoclonal mAbs.
Keywords: aDcc, cetuximab-activated nK cells, hnscc tumor spheroids, soluble Mica, TgF-β1
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surveillance capacity of sMICA-inhibited NK cells from HNSCC 
patients (n = 5), thus demonstrating the potential usefulness of 
cetuximab in retargeted ADCC. In order to investigate specific 
NK cell-dependent tumor infiltrations and ADCC-related 
cetuximab response, we developed HNSCC tumor-like cell 
clusters and a tumor spheroid model derived from primary, 
singularized tumor cells from these HNSCC patients. Our 
results indicate a crucial relevance of enhanced sMICA levels in 
tumor surveillance and infiltrations of inhibited patient NK cells. 
Finally, we demonstrate that these immunosuppressive effects 
on NK cell-mediated killing activity could be bypassed using 
cetuximab-coated HNSCC cells.
PaTienTs anD MeThODs
hnscc Patients
We analyzed five HNSCC patients (three male and two female, 
age range: 24–76  years) and five age-matched healthy indi-
viduals (three male and two female, age range: 26–58  years) 
served as controls. Histopathology confirmed that patients had 
stage II–IV HNSCC. Patients were included in this study after 
tumor recidivism but before initiation of any clinical treatment 
(Table 1). Corresponding patient blood samples (80–100 ml) 
were received shortly before the tumor surgery and associated 
tumor fragments were collected during tumor extractions from 
all patients. Informed consent was obtained from patients, 
caretakers, and healthy controls (HCs). Patient characteristics 
are summarized in Table 1. Blood samples were collected from 
HNSCC patients and healthy individuals in Heparin- and 
EDTA-coated tubes. Total leukocytes and the resultant sub-
populations were counted by five-color flow cytometry (FCM) 
analysis as described previously (44). Immunocompetent cell 
subpopulation distributions were compared among patients 
and HCs (Figure 1).
Target cell line
The human HNSCC cell line SCC-4 (ATCC: CRL-1624) (45, 46) 
was used to compare the cytotoxic activities of freshly purified 
patient and healthy NK cells and served as an internal control 
for scored intensities of comparable fluorescence staining’s from 
different patient-derived primary HNSCC cells. Therefore, 
the SCC-4 was cultured in DMEM and GlutaMAX™ medium 
(GIBCO, Invitrogen, Germany) supplemented with 10% (v/v) 
heat-inactivated fetal bovine serum (FBS) and 2 mM l-glutamine 
(PAA Laboratories GmbH, Austria).
Preparation of single cell suspension 
from Primary Tumor samples
Tumor samples from untreated HNSCC patients (n =  5) were 
collected post-surgery and washed twice in serum-free DMEM/
F12HAM/Glutamax supplemented with 100  U/ml penicillin, 
100 μg/ml streptomycin, 0.25 μg/ml amphotericin B (antibiotic–
antimycotic 100×, all purchased from Life Technologies, Gibco®, 
Darmstadt, Germany). After dissociation with 0.05% trypsin/
EDTA (Life Technologies, Gibco®, Darmstadt, Germany), tumor 
pieces were minced with scissors and scalpels in a sterile dish. 
The digestion was stopped with DMEM/F12HAM/Glutamax 
containing 10% AB-Serum (former: PAA, Linz, Austria), anti-
biotic–antimycotic and the sample was passed through a 70 or 
100-μm nylon mesh cell strainer (BD Biosciences, Heidelberg, 
Germany) to achieve single cell suspensions. Cells were collected 
in a 50-ml conical tube and subsequently centrifuged. Suspended 
cells were counted with trypan blue, characterized with FCM 
and cultivated in DMEM/F12HAM/Glutamax/10% AB serum/
antibiotic–antimycotic in an incubator (37°C, 5% CO2, 90% 
humidity). Cultured tumor cells formed small tumor cell clusters 
after a few days, which resulted in tightly arranged HNSCC tumor 
spheroids (diameter: 1–3 mm) after cell cultivation of 1–2 weeks. 
Tumor cluster and spheroids derived from our HNSCC patients 
were used for NK cell-based cytotoxicity and tumor-infiltration 
assays monitored by fluorescence microscopy and time-lapsed 
transmitted imaging.
cytokine analysis
The BD CBA Kit was utilized for scavenging soluble cytokines, 
especially IFN-γ and TNFα with beads of known size and fluo-
rescence, allowing identification of soluble molecules in blood 
or supernatants from cell culture medium by FCM as described 
previously (44).
TaBle 1 | The clinical parameters and immune status of hnscc (n = 5) patients summarized after tumor (TU) and lymph node (ln) surgery but before 
any acute clinical therapeutic regimens.
Patient characteristics 1 2 3 4 5
Age (years) 24 69 66 76 29
TNM classification T2N2M1 T3N2M1 T3N2M1 T1N1M0 T2N2M0
Grading 2 2 2 1 2
Treatment/chemotherapy Surgery/− Surgery/− Surgery/− Surgery/− Surgery/−
TU/LN locations Neck/ear Upper gingiva/lower jaw Neck/ear Jaw angle Tongue
TU/LN material for research +/− +/+ +/+ +/+ +/−
immune status Leukocytes (cells/μl) 11,000 6250 8000 4900 8200
Lymphocytes (% of leukocytes) 13.6 19.4 14.6 11.5 43.2
Monocytes (% of leukocytes) 10.5 4.5 8.9 6.6 6.2
T cells (% of lymphocytes) 74.7 70.1 82.7 82.2 54.9
B cells (% of lymphocytes) 11.2 1.9 12.1 6.2 5.0
NKT cells (% of lymphocytes) 1.1 7.5 1.7 1.3 3.4
NK cells (% of lymphocytes) 12.8 19.5 2.7 9.3 33.2
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NK cells (Figures 2 and 3). Singularized HNSCC cells were also 
tested for MICA, HER2, and HER1 surface expression, the latter as a 
target for restored ADCC before initiation of described cytotoxicity 
assays. To determine the effect of cetuximab on NK cell-dependent 
killing activity, various cetuximab doses (Cetmab: 1 pg/ml–1 μg/
ml) were used to coat the corresponding HNSCC target cells 
(E:T ratio: 10:1). To inhibit putative effects of cetuximab toward 
NK  cell-mediated cytotoxicity, the NK cells were pre-incubated 
for 20  min with anti-CD16 mAb (20 μg/ml). The effector-based 
 cytotoxicity of these treated NK cell samples were analyzed against 
corresponding patient HNSCC cells in the indicated effector-
to-target ratios (Figures  3 and 4). To avoid effector and target 
cell sedimentations or insufficient stirring of our co-incubated 
approaches during the cytotoxic reactions, the co-cultured cell 
suspensions were shaken in an CO2-incubator (CO2cell, 170-400 
Plus, RS Biotech, Scotland) for 4 h (37°C, 5% CO2, 250 rpm). An 
optimized gating panel (Figure S1 in Supplementary Material) 
based on a no-wash single platform FCM procedure (FC500, 
Beckman Coulter, Germany) was applied. Treated NK cells were 
stained with several monoclonal antibodies (mAbs): CD45 FITC 
(fluorescein isothiocyanate), CD56 PE ( phycoerythrin) or NKG2D 
PE, CD16 PC-7 (phycoerythrin-cyanin-7) in order to exclude the 
effector cells from primary HNSCC target cells stained with CD9 
FITC, CD9 PE, HER1 PE, MICA PE, or CD81 PE. Effector and 
target cells were stained with mAbs as described previously (47, 48). 
Target cell elimination by effector cells was calculated as the total 
loss of viable HNSCC target cells as follows (48, 49):
 
Killing activity concentrationco-cultured HNSCC cells/= −(1 µL
HNSCC control cells/ Lconcentration
/
) %µ ×100  
Fluorescence Microscopy
IL-2 activated patient NK cells were cultured (24  h) with PP 
[(high sMICA); 1:2 diluted with X-VIVO™10] or healthy plasma 
[HP (low sMICA); 1:2 diluted with X-VIVO™10]. Afterward, 
these treated NK cells were co-incubated (1  h, 37°C, 5% CO2, 
approximate E:T ratios of 5:1) on 4-well chamber slides (1.7 cm2 
growth area/well, 0.5–1.0  ml working volume, Nunc™, USA) 
with corresponding adherent HNSCC cell clusters derived from 
HNSCC patients (n = 5, time of cultivation: 3–12 days) in pres-
ence or absence of 1 μg/ml cetuximab for indicated periods of 
time (Figure 5A). The capability of tumor infiltration from those 
treated patients NK cells (see above) in corresponding patient 
HNSCC tumor spheroids (n = 5) were assessed with and without 
1 μg/ml cetuximab and analyzed after 24 h co-cultivation (37°C, 
5% CO2) (Figure  6). 2D/3D confocal fluorescence microscopy 
(CFM) using FITC- and PE-conjugated mAbs was used to sepa-
rate stained patient NK cells (CD45 FITC or NKG2D PE) and cor-
responding HNSCC cell clusters or tumor spheroids (CD9 FITC, 
HER1 PE, HER2 PE, or MICA PE), as described before (47).
Time-lapse Microscopy
Transmission microscopy was used to monitor infiltration of 
sMICA-inhibited NK cells into corresponding HNSCC tumor 
spheroids. Low numbers of tumor spheroids were grown scat-
tered on chamber slides for 16 h (37°C, 5% CO2). Subsequently, 
FigUre 1 | Phenotypical and functional characterizations of patient nK cell subsets and primary tumor cells from non-treated hnscc patients 
(n = 5) after tumor relapse. (a) In vitro rearrangement of the NK cell phenotype was quantified in the PB before separation of NK cells and after IL-2 expansion 
(1000 IU/ml IL-2; 9–12 days). Shown are the absolute numbers of patient (HNSCCNK cells) and healthy donor (HDNK cells) CD56+/CD3− NK cells [cells/μl] [left graph area 
(NK)], the mean fluorescence intensity [MFI (%)] of distribution of resultant CD56bright/CD16dim&neg and CD56dim/CD16+ NK subpopulations [middle graph area 
(subsets)] and co-expressed NCRs [MFI (%) right graph area (NCRs)] among total NK cells. (B) SMICA and TGF-β1 levels were analyzed in blood plasma from 
corresponding HNSCC patients (PP) and compared to age-matched healthy donor plasma controls (HP). (c) Assessment of the basic killing activities between 
effector cells isolated from patient and healthy donor NK cells against SCC-4 target cells. Freshly isolated, non-stimulated NK cells from patients (HNSCC), and 
healthy controls (HC) were treated with corresponding HNSCC patient plasma (high sMICA/TGF-β1) or associated healthy control plasma (low sMICA/TGF-β1) and 
co-incubated for 4 h (37°C, 5% CO2, 250 rpm) with SCC-4 cells at the indicated E:T ratios and cytotoxicity (%) was measured by FCM. (D,e) Immunofluorescence 
staining and FCM-based characterization of relevant tumor antigen expression from primary tumor samples derived from corresponding HNSCC patients (n = 5). 
After preparation of single cell suspensions from primary tumor samples, tumor cells were cultured (1–2 days, 37°C, 5% CO2) on chamber slides and characterized 
phenotypically for CD9, MICA, HER1, and HER2 expression profiles by immunofluorescence microscopy. Depicted is the staining for one representative HNSCC 
sample. (D) The HNSCC cells were also analyzed for CD9 (FITC), MICA (PE), HER1 (PE), and HER2 (PE) surface expression levels by FCM (e). Nuclei were stained 
with DAPI (4′,6-diamidino-2-phenylindole, blue fluorescence). (F) Secretion of soluble immunosuppressive factors derived from five tumor samples. SMICA and 
TGF-β1 levels in expanded primary HNSCC cell cultures were analyzed by ELISAs in the collected cell medium supernatants at the indicated time frames. (a–F) Data 
are shown as mean ± SD from two to four experiments for the five patients. Range of statistically significant differences: from *p ≤ 0.01 to **p ≤ 0.001.
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Quantification of sMica and TgF-β1 in 
hnscc Patients
The BAMOMAB MICA-Sandwich ELISA kit for sMICA (AXXORA 
GmbH, Germany) was designed for quantification of soluble 
MICA (sMICA). The kit was utilized for detection and monitoring 
of immunosuppressive molecules in HNSCC patient blood plasma 
(n = 5), HCs (n = 5), and supernatants of cell culture medium dur-
ing adherent growth phase of tumor cell clusters and generation 
of tumor spheroids as described previously (47). TGF-β1 levels in 
human blood plasma samples and cell culture supernatants were 
quantified by MTPL ELISA (Milenia Biotec, Version 3.0, Germany).
immunomagnetic separation of 
cD56+cD3− nK cells
Up to 100 ml heparinized blood from HNSCC patients (n = 5) 
was used to isolate viable mononuclear cells (MNC) in high yield 
and purity by Ficoll-Paque density gradient. Primary NK cells 
were separated from purified MNCs via “non-touched” depletion 
using the EasySep® Human NK Cell Enrichment Kit (STEMCELL 
Technologies SARL, Germany). Other leukocyte subsets were 
labeled with tetrameric antibody complexes against CD3, CD4, 
CD14, CD19, CD20, CD36, CD66b, CD123, HLA-DR, glyco-
phorin A, and dextran-coated magnetic particles. The non-labeled 
cells were scavenged by an EasySep® hand magnet according to 
the manufacturer’s recommendations. Freshly purified NK cells 
(purity: 95.1 ± 2.8%) were expanded and activated with 1000 IU/
ml IL-2 for 9–12 days as described previously (47).
Production of shed Mica
To generate shMICA, the DNA sequence encoding for full length 
MICA engineered with an N-terminal histidine-tag was cloned 
into a tet-on vector system and transfected into the UKF-NB3 
tumor cell line using the Neon transfection system (Life 
Technologies, USA). Cells were selected with 0.25 mg/ml G418 
and 1 μg/ml puromycin (Life Technologies, USA). MICA expres-
sion was induced by addition of 2 μg/ml doxycycline (Sigma, 
Germany). Further on cells were stressed by serum starvation 
for 72 h to induce MICA shedding. Finally shMICA was puri-
fied with Protino Ni-NTA agarose (Macherey-Nagel, Germany) 
from cell culture supernatants and concentrated using Amicon 
centrifugal filter units (Merckmillipore, Germany).
cytotoxicity assays
To analyze the NK cell-mediated killing activity in presence and 
absence of cetuximab, we developed a matched effector-target cell 
system based on a FCM-based cytotoxicity assay. Therefore, we 
utilized only concordant patient NK cells, patient plasma (PP, high 
sMICA) and primary patient HNSCC tumor cells (n = 5). To demon-
strate the sMICA-mediated inhibition, IL-2 expanded (9–12 days) 
primary patient NK cells were co-incubated overnight (24 h, 37°C, 
5% CO2, 250 rpm) with 500 pg/ml shMICA, PP containing high 
MICA levels (PP, range: 220.9–870.7 pg/ml) and, as a comparative 
control, with HC plasma (HP, range: 2.8–22.0 pg/ml) diluted 1:2 
in X-VIVO™10 medium (Biowhittacker™Cambex Bioscience, 
Belgium). Phenotypical cell characterizations were accomplished to 
detect altered expression patterns of CD16 and NKG2D on treated 
NK cells (Figures 2 and 3). Singularized HNSCC cells were also 
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target for restored ADCC before initiation of described cytotoxicity 
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for 20  min with anti-CD16 mAb (20 μg/ml). The effector-based 
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Killing activity concentrationco-cultured HNSCC cells/= −(1 µL
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/
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effector cells isolated from patient and healthy donor NK cells against SCC-4 target cells. Freshly isolated, non-stimulated NK cells from patients (HNSCC), and 
healthy controls (HC) were treated with corresponding HNSCC patient plasma (high sMICA/TGF-β1) or associated healthy control plasma (low sMICA/TGF-β1) and 
co-incubated for 4 h (37°C, 5% CO2, 250 rpm) with SCC-4 cells at the indicated E:T ratios and cytotoxicity (%) was measured by FCM. (D,e) Immunofluorescence 
staining and FCM-based characterization of relevant tumor antigen expression from primary tumor samples derived from corresponding HNSCC patients (n = 5). 
After preparation of single cell suspensions from primary tumor samples, tumor cells were cultured (1–2 days, 37°C, 5% CO2) on chamber slides and characterized 
phenotypically for CD9, MICA, HER1, and HER2 expression profiles by immunofluorescence microscopy. Depicted is the staining for one representative HNSCC 
sample. (D) The HNSCC cells were also analyzed for CD9 (FITC), MICA (PE), HER1 (PE), and HER2 (PE) surface expression levels by FCM (e). Nuclei were stained 
with DAPI (4′,6-diamidino-2-phenylindole, blue fluorescence). (F) Secretion of soluble immunosuppressive factors derived from five tumor samples. SMICA and 
TGF-β1 levels in expanded primary HNSCC cell cultures were analyzed by ELISAs in the collected cell medium supernatants at the indicated time frames. (a–F) Data 
are shown as mean ± SD from two to four experiments for the five patients. Range of statistically significant differences: from *p ≤ 0.01 to **p ≤ 0.001.
FigUre 2 | impact of sMica on nKg2D surface expression and nKg2D-mediated nK cell cytotoxicity against hnscc cells. Isolated CD56+/CD3− NK 
cells from untreated HNSCC patients (n = 5) were stimulated for 9–12 days with 1000 IU/ml IL-2. (a) Effect of high sMICA levels on NKG2D surface expression. IL-2 
activated patient NK cells were incubated (37°C, 5% CO2) at the indicated points of time with shMICA (500 pg/ml), rMICA (500 pg/ml) and patient plasma containing 
high MICA levels (PP, range: 220.9–870.7 pg/ml). The NKG2D expression levels on total NK cells and both CD56dim/CD16+ and CD56bright/CD16dim&neg NK subsets 
were compared to non-treated control NK cells. (B) Phenotypical analyses on time-dependent impact of shMICA on NKG2D surface expression were determined by 
FCM. Exemplarily depicted here are representative dot plots for one time-dependent experiment.
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FigUre 3 | Determination of the sMica impact on aDcc-stimulating and pro-apoptotic nK cell receptors. (a) Surface expression levels of CD16, TRAIL, 
FasL, and CD57 on the same effector cell samples were measured at the indicated time points and compared to non-treated control cells. As an additional control, 
effector cell viability was monitored over a 24-h period (B–D). The impact of sMICA on the NKG2D-mediated NK cell cytotoxicity and NK cell stability during 
effector-target interactions against primary HNSCC cells (n = 5) was analyzed by FCM. Therefore, the same overnight-treated NK cell samples (see above, section 
Figure 2a) were subsequently co-incubated for 4 h (37°C, 5% CO2) with corresponding patient HNSCC target cells at the indicated E:T ratios. (e) Inhibition of 
sMICA effects on NKG2D-mediated NK cell cytotoxicity. SMICA molecules in all treatment samples (shMICA, rMICA, and PP) were blocked by pre-incubation 
(20 min) with MICA-specific mABs (20 μg/ml, MAB13001). NKG2D-dependent killing rates of those incubated NK cells against primary HNSCC cells were measured 
after 4 h (“Blocking assays,” ratio: 10:1, 37°C, 5% CO2) as described above. Data are shown as mean ± SD from three to four experiments for each patient. 
Statistically significant difference: *p ≤ 0.01 and **p ≤ 0.001.
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FigUre 4 | restored killing activity against primary hnscc cells mediated by cetuximab.  
 (Continued)
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IL-2 activated patient NK cells (n = 5) were incubated for 24 h (37°C, 5% CO2) with (a) shed MICA (shMICA, 500 pg/ml), (B) with patient plasma containing high 
MICA levels (PP, n = 5, range: 220.9–870.7 pg/ml) and healthy plasma (HP, n = 5, range: 1.9–28.5 pg/ml) served as a control. (a) CD16-mediated ADCC of those 
treated patient NK cells was assessed by FCM-based cytotoxicity assay using cetuximab (Cetmab, range of dose titration: 1 μg/ml–1 pg/ml)-coated primary 
HNSCC cells and compared to killing activity of shMICA-treated NK cells against non-coated HNSCC cells. (B) To overcome sMICA effects against NK cell 
cytotoxicity, 1 μg/ml cetuximab was chosen based on the earlier titration experiments (see above). Inhibition of cetuximab-dependent ADCC was achieved by 
blocking CD16 epitopes on treated patient NK cells with anti-CD16 mAb [20 μg/ml, 20 min pre-incubation, graphs (a,B)]. (c) The effector cell stability of PP- and 
HP-treated viable NK cells during tumor cell lysis was analyzed in presence and absence of 1 μg/ml cetuximab and compared to non-treated effector cell controls 
quantified by single platform functionality assays. (D) FCM-based characterization was utilized to monitor CD16 and NKG2D surface expression patterns on treated 
NK cells (CD16/NKG2D, see overlay histograms) before (−PP) and after (+PP) overnight incubation with patient plasma (PP) containing high sMICA and TGF-β1 
levels. Analogously, HNSCC cell clusters were singularized for FCM-based characterization of target cell antigens (HER1/HER2/MICA) to assess alterations in the 
killing activity from different treated patient NK cells. (e) Effect of IL-2 on the killing activity of patient NK cells (n = 5) in presence (+IL-2/+Cetmab) and absence 
(+IL-2) of 1 μg/ml cetuximab (Cetmab). IL-2 expanded NK cells were incubated with patient plasma containing high MICA levels (PP, n = 5, range: 220.9–870.7 pg/
ml), healthy plasma (HP, n = 5, range: 1.9–28.5 pg/ml) and control medium. Cytotoxicity of treated NK cells was analyzed at the indicated ratios with and without 
Cetmab (1 μg/ml)-coated primary patient HNSCC cells and compared to killing activity of unstimulated NK cells against non-coated HNSCC cells (−IL-2). (a–D) 
Data represent the mean ± SD of three experiments for each patient. Statistically significant difference: *p ≤ 0.01 and **p ≤ 0.001.
FigUre 4 | continued
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HNSCC spheroids were co-incubated with freshly isolated, 
non-stimulated patient NK cells (1  ×  106  effector cells/ml). 
Putative effector cell migration and tumor chemoattraction were 
monitored by time-lapse microscopy and imaging (Video S1 in 
Supplementary Material) as described previously (47).
Blocking assays
To inhibit the restored NK cell-based cytotoxicity by cetuximab, 
patient NK cells were pre-incubated for 20 min with anti-CD16 
mAb (clone 3G8, 20 μg/ml, A07766, Beckman Coulter, Germany). 
Afterward, killing activity of treated NK cells was analyzed with 
cetuximab-coated primary patient HNSCC cells over a time 
period of 4 h (37°C, 5% CO2, 250 rpm) at an E:T ratio of 10:1 
and compared to corresponding controls (Figure 4) as described 
previously (47). To analyze the direct role of sMICA on NKG2D-
mediated cytotoxicity, we incubated IL-2-activated patient NK 
cells with shMICA, rMICA, and PP containing high sMICA levels 
overnight in the presence or absence of specific MICA antibodies, 
respectively (20  μg/ml, MAB13001, R&D systems, Germany). 
Additionally, plasma from five healthy donors (low sMICA, see 
above) was utilized to incubate patient NK cells as a control.
statistical analyses
The Mann–Whitney non-parametric U-test was utilized to 
compare clinical and pathological parameters of plasma sMICA 
and TGF-β1 levels from HNSCC patients (n =  5) with healthy 
individuals (n = 5). The Student’s t test was used to assess the sig-
nificance of the killing activity of patient NK cells incubated under 
various conditions. A p level ≥0.01 was considered statistically as 
non-significant. Unless otherwise declared, results of statistical 
evaluations from functional assays are indicated as mean ± SD 
and represent three to four experiments for each patient.
resUlTs
characterization of altered nK cell 
subsets and expression of ncrs in 
hnscc Patients
Compared to age-matched healthy individuals (50), HNSCC 
patients showed a broad range of leukocyte subpopulations and 
absolute numbers of lymphocytes and leukocytes (Table  1). 
Although median NK cell amounts (12.8%; range: 2.7–33.2%) 
did not differ from HCs (Table 1), the absolute NK cell numbers 
(cells/μl) differed widely in the peripheral blood (PB) of patients 
and healthy donors (left graph sector, Figure  1A). Moreover, 
the proportion of immunoregulatory NK cells (CD56bright/
CD16dim&neg) was markedly reduced in all patients [median: 
2.4% (HNSCCNK cells) versus 11.8% in healthy donors (HDNK 
cells), middle graph sectors, Figure 1A]. In contrast, the cytotoxic 
NK cell subpopulation (CD56dim/CD16+) was strongly increased 
for all investigated HNSCC patients [median (HNSCCNK cells): 
96.2% versus 86.8% (HDNK cells), middle graph sector, Figure 1A]. 
Moreover, freshly isolated patient NK cells revealed low to mod-
erate expression levels of the NCRs, NKp30, NKp44, NKp46, 
and NKG2D compared to higher frequencies of IL-2 stimulated 
NK cells from HCs (right graph sector, Figure 1A). Nevertheless, 
the percentage of NK cells expressing NCRs increased (~4.7-fold, 
3.8-fold, and 2-fold for NKp30, NKp44, and NKp46, respectively) 
during IL-2 activation over 9–12 days and was accompanied by 
~60.7-fold higher expression levels of NKG2D (Figure 1A, right 
graphs) for all stimulated patient NK cells. The distribution of 
NK cell subpopulations shifted to higher CD56bright/CD16dim&neg 
NK cell subsets (median before IL-2: 2.4% versus median after 
IL-2: 12.5%) and consequently lower percentages of CD56dim/
CD16+ NK cells (median before IL-2: 96.2% versus median after 
IL-2: 88.9%) (Figure 1A).
reduced nK cell-Dependent cytotoxicity 
and increased immunosuppressive 
Factors in hnscc Patients
The well-defined immunosuppressive factors sMICA and 
TGF-β1, which are responsible for impaired immunosurveillance, 
were quantified in PB from our HNSCC patients. Higher levels of 
both soluble factors were detected in HNSCC patients compared 
to HCs (sMICA, median: 532.8 versus 5.9 pg/ml; TGF-β1, median: 
48.9 ×  104 versus 10.9 ×  104  pg/ml, respectively) (Figure  1B). 
Healthy plasma samples showed sMICA and TGF-β1 levels 
close to the detection limits of this assay [sMICA (mean ± SD): 
10.8 ±  11.2  pg/ml; TGF-β1: 9.5 ±  5.2 ×  104  pg/ml; Figure  1B, 
HP], whereas sMICA (TGF-β1) in PP ranged between 220.9 and 
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870.7 pg/ml (25–64.8 × 104 pg/ml) (Figure 1B, PP). To compare 
the basic killing activity between patient NK cells and NK cells 
from healthy individuals, freshly isolated, non-stimulated NK 
cells from both, patients and HCs were co-incubated overnight 
(37°C, 5% CO2) with corresponding HNSCC PP (high sMICA/
TGF-β1) or associated HC plasma (low sMICA/TGF-β1). In both 
cases, the NK cell-mediated cytotoxicity was analyzed against the 
target cell line SCC-4 at the indicated ratios (4 h, 37°C, 5% CO2, 
250 rpm) by FCM (Figure 1C). HNSCC plasma-treated patient 
NK cells (HNSCC, Figure  1C) exhibited significantly reduced 
cytotoxicity in all prepared E:T ratios when compared to NK cells 
from healthy donors pre-incubated with the corresponding HC 
plasma (Figure 1C).
Phenotypical analysis of Tumor-relevant 
expression Markers on Primary Patient 
hnscc cells
Expression levels of relevant surface antigens, especially HER1 
and HER2, were examined on single tumor cell suspensions 
prepared from primary tumors surgically removed from HNSCC 
patients (n = 5, see above). Pre-characterized SCC-4 cells were 
utilized as a positive control for HER1 and HER2 expression 
because it was previously shown that these HNSCC cells displayed 
high amplification rates of HER1 genes in combination with 
enhanced HER2 and MICA expression levels (51). In addition to 
the HER1/2 levels, we analyzed expression levels of surface mark-
ers CD9 and MICA on the mono-dispersed patient tumor cells 
(Figure  1E). Representative overlay plots (FCM) were shown 
exemplarily in Figure 1E for prepared tumor cells derived from 
one HNSCC patient and were compared with qualitative evalua-
tions determined by CFM. In Figure 1D, representative results of 
overlapping CFM exemplarily illustrated for cultured (1–2 days) 
adherent patient tumor cells after fluorescence labeling with simi-
lar stimulation energy and duration are shown. For counterstain-
ing, we utilized DAPI as a fluorescent stain that binds strongly 
to A–T rich DNA regions of nuclei and chromosomes and emits 
blue fluorescence (Figure 1D). All tumor samples showed higher 
HER1 and CD9 levels in contrast to low-to-moderate expression 
of membrane-associated MICA and HER2 molecules. In sum-
mary, the antigens exhibited variable expression levels on all 
tumor samples of HNSCC patients and were slightly lower than 
on the SCC-4 control line as presented in Table 2.
Primary patient HNSCC cells (n  =  5) were cultured over 
2  weeks (37°C, 5% CO2) to investigate time-dependent accu-
mulation of immunosuppressive factors (sMICA and TGF-β1), 
and cell culture supernatants were collected at the indicated 
time periods (Figure  1F). A time-dependent increase of both 
TaBle 2 | antigen expression levels measured on singularized patient hnscc cells (n = 5) after preparation from tumors.
scc-4 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
HER1 +++ ++ +++ ++ +++ ++
HER2 +++ +/− +/− + + +
MICA ++ +/− + +/− + +
CD9 +++ ++ ++ ++ + ++
Fluorescence labeling of these tumor cells were compared to the SCC-4 cell line and intensities were scored as follows: weak (+/−), moderate (+), good (++), and strong (+++).
immunosuppressive molecules was identified in cell culture 
supernatants in which the mean of sMICA levels increased from 
18.7 ± 9.5 to 218.7 ± 131.9 pg/ml, and the mean of TGF-β1 levels 
increased from 6.8 ± 4.8 × 104 to 40.9 ± 11.6 × 104 pg/ml between 
the first and last time points monitored (Figure 1F).
sMica affects nKg2D expression and 
cytotoxicity of il-2-activated Patient 
nK cells
Tumor-derived TGF-β1 potentiated the sMICA-mediated down-
regulation of NKG2D surface expression on various effector cells, 
especially NK cells, and resulted in decreased NKG2D-dependent 
immunity, thus reflecting the predominant role of the sMICA-
NKG2D system (20, 52). Therefore, we co-cultured IL-2-activated 
patient NK cells overnight (24 h) with sMICA analogs (shMICA 
and rMICA, each in 500 pg/ml) and PP containing high sMICA 
levels (range: 220.9–870.7 pg/ml). All incubated NK cell samples 
from the five HNSCC patients exhibited a time-dependent down-
regulation of NKG2D expression on total NK cells and both NK 
cell subsets (Figures 2A,B), whereas surface expression of CD16, 
pro-apoptotic FasL, and TRAIL receptors as well as activation 
marker CD57 were largely unaffected and stable over the indi-
cated time period on all NK cell fractions by the described sMICA 
analogs (Figure 3A). We detected a distinct effect of shMICA on 
NKG2D expression on total NK cells and resultant NK subpopu-
lations analyzed during the indicated time frame of 24 h (37°C, 
5% CO2) by FCM. The time-dependent NKG2D down-regulation 
is displayed in plots exemplarily shown for one experiment 
(Figure 2B). Although surface phenotype, cell proportions, and 
viability of NK cells were not affected by co-incubation with PP 
(24 h, high MICA, Figure 3A), the observed decrease of NKG2D 
surface expression was accompanied by reduced IFN-γ and 
TNFα secretion compared to IL-2 activated patient NK cells [IL-2 
(9–12 days), Figure 5D].
Additionally, the impact of sMICA on the NKG2D-mediated 
NK cell cytotoxicity of overnight co-incubated NK cells was 
analyzed against corresponding primary tumor cells derived from 
HNSCC patients (n = 5) to assess the degree of killing activity. 
Effector and target cells were co-incubated for 4 h (37°C, 5% CO2, 
250 rpm) at indicated E:T ratios and killing activity was subse-
quently compared to X-VIVO™10-incubated controls without 
sMICA analogs. The cytotoxicity of shMICA- and PP-treated 
NK cells was strongly suppressed compared to low inhibition 
frequencies of rMICA-incubated effector cells at all E:T ratios 
(Figures  3B–E). During the cytotoxicity assays of co-cultured 
effector and target cells, the NK cell viability was decreased in 
shMICA-, rMICA-, and PP-treated NK cells as compared to 
FigUre 5 | restored effector-target cell interactions via cetuximab-dependent aDcc of sMica-inhibited nK cells. (a) Activated patient NK cells were 
cultured (24 h) with patient plasma (PP; 1:2 diluted with X-VIVO™10) containing high sMICA levels and co-incubated (1 h, approximate E:T ratios of 5:1) with 
corresponding HNSCC cell clusters (time of cultivation: 3–12 days) in (i) presence and (ii) absence of 1 μg/ml cetuximab. (iii) Activated patient NK cells treated for 
24 h with healthy plasma (HP [low sMICA]; 1:2 diluted with X-VIVO™10) were used to monitor early effector-target cell interactions, served as a positive control. 
CD45 (green) for PP- and HP-treated patient NK cells were analyzed by staining with FITC-conjugated mAb, whereas co-incubated adherent HNSCC clusters were 
unlabeled. Before initiating these functional assays, effector and target cells were tested flow cytometrically for relevant surface markers, especially MICA, HER2 and 
HER1 on HNSCC cells (B), and CD16 and NKG2D levels on PP (high sMICA/TGF-β1)-treated NK cells (c). Variable IFN-γ and TNFα secretions levels during 
co-incubations of treated NK cells with HNSCC cell clusters or tumor spheroids in presence or absence of cetuximab were quantified and compared with untreated 
controls (D). Statistically significant difference: *p ≤ 0.01 and **p ≤ 0.001.
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more stable effector cells in X-VIVO™10-incubated controls 
(Figures  3B–E). To confirm the direct sMICA impact on the 
NKG2D-mediated NK cell cytotoxicity, MICA-specific mAbs 
(20 μg/ml, MAB13001) were used to deplete sMICA molecules 
in different treatment mixtures (shMICA, rMICA, and PP) 
(Figure  3E). NK cell cytotoxicity of these treated effector cells 
co-incubated with corresponding primary HNSCC cells were 
compared with sMICA analog-treated NK cells co-cultured with-
out sMICA-specific mAbs as a negative control. The diminished 
killing activity of sMICA-affected NK cells was partially restored 
when compared to untreated (X-VIVO™10) control effector cells 
and to NK cells pre-treated with healthy plasma (HP, low sMICA) 
(Figure 3E).
cetuximab restores nK cell-Dependent 
cytotoxicity against Primary hnscc cells 
via aDcc
Cetuximab is a therapeutic mAb directed against the HER1 epitopes 
on several types of high-malignant tumors (53). Consequently, 
cetuximab is a powerful stimulus of NK cell-mediated ADCC 
via activation of FcγRIIIa against cetuximab-coated tumor cells 
and for induction of cytokine release, especially IFN-γ and TNFα 
secretion. Figure 4A demonstrates significantly restored NK cell-
based cytotoxicity against cetuximab-coated HNSCC cells with 
mAb concentrations of 1 μg/ml (mean: 43.8 ± 10.8%) and 1 ng/
ml (mean: 38.4 ± 6.8%) as compared to reduced killing activity 
of shMICA-incubated NK cells (mean: 13.4 ±  11.2%) against 
non-coated HNSCC cells and anti-CD16 mAb-blocked NK cells 
(mean: 28.8 ± 8.9%). Based on these titration experiments, only 
1 μg/ml cetuximab were applied in subsequent experiments to 
restore the decreased NK cell cytotoxicity (mean: 41.5 ± 6.3%) 
after overnight incubation with PP (high sMICA, mean of 
cytotoxicity: 26.1 ± 6.3%) and blocking experiments with anti-
CD16 mAb-treated NK cells (mean of cytotoxicity: 24.8 ± 5.7%) 
(Figure 4B). Untreated (X-VIVO™10) and healthy plasma (HP, 
low sMICA)-incubated patient NK cells were defined as unaf-
fected control cells. NK cell viability was affected exclusively 
by PP-treatment and HP-incubated NK cells exhibited similar 
viability levels as untreated effector cells (Figure 4C). As internal 
effector cell controls, we assessed the activation marker NKG2D 
and IgG Fc receptor (CD16) of PP-treated (high sMICA) NK cells 
after 24 h overnight incubation by FCM. As shown in Figure 4D 
(upper row), the expression of NKG2D was significantly decreased 
but the CD16 expression levels were not changed on these effector 
cells. Otherwise, the phenotypical characterizations of target cell 
parameters showed higher levels of HER1 and HER2 antigens 
and only low-to-moderate MICA expressions on corresponding 
patient HNSCC cells (Figure 4D, lower row).
To determine whether IL-2 potentiates the cetuximab-medi-
ated outcome on restored effector cell cytotoxicity against HNSCC 
cells, we analyzed the degree of ADCC from X-VIVO™10-, 
PP-, and HP-treated patient NK cells against cetuximab-coated 
and non-labeled HNSCC cells in the presence or absence of 
IL-2 (Figure 4E). Reconstituted NK cell cytotoxicity via ADCC 
was detected against cetuximab-coated HNSCC cells (IL-2 and 
Cetmab) compared to decreased cytotoxicity of PP-incubated NK 
cells against non-labeled HNSCC cells independently from the 
presence (+IL-2) or absence of IL-2 (Figure 4E, middle graph). 
Combination of IL-2 with cetuximab-coated or non-coated 
HNSCC cells (IL-2 with Cetmab or IL-2 alone) revealed no 
improvement of ADCC from X-VIVO™10- and HP-treated NK 
cells, but inclusion of IL-2 significantly enhanced NK cell cyto-
toxicity compared to untreated NK cells (-IL-2) (Figure 4E, left/
right graphs). The cetuximab-mediated reconstitution of NK cell 
cytotoxicity correlated with higher IFN-γ and TNFα secretion 
levels (24 h PP + 1 μg/ml Cetmab + 4 h HNSCC cells) compared 
to PP-treated NK cells [24 h PP (high MICA) Figure 5D].
cetuximab reconstitutes nK cell 
infiltration into hnscc clusters and 
Tumor spheroids
To assess the capability of tumor infiltrations from sMICA-
affected patient NK cells in absence or presence of 1  μg/ml 
cetuximab, we developed different in vitro models by establish-
ing co-cultures (37°C, 5% CO2). Therefore, activated patient NK 
cells were pre-incubated overnight with corresponding PP (high 
sMICA) or healthy plasma (HP, low sMICA) served as a positive 
control. Afterward, the early recognition and tumor-infiltration 
capabilities of these treated effector cells were monitored after 1 h 
co-incubation with primary HNSCC cell clusters (Figure 5) or 
after 24 h in HNSCC tumor spheroids derived from five HNSCC 
patients to identify specific tumor-infiltrated NK cells (Figure 6).
Early “effector-to-target” affinities of treated NK cells against 
adherent HNSCC cell clusters coated or not coated with 1 μg/
ml cetuximab were monitored (10  min–1  h) by CFM. The 
experiments showed clearly impaired and disordered “effector-
to-target” interactions and decreased HNSCC cell cluster 
infiltrations from PP-treated NK cells in absence of cetuximab 
(Figure  5A, one row) compared to normal tumor infiltration 
capabilities of HP-treated (low sMICA) NK cells, served as a 
positive control [Figure 5A, lower row, right picture (control)]. 
In contrast, early effector cell-dependent infiltration within 
20–30  min and restored anti-tumor reaction was observed by 
PP-treated NK cells against cetuximab-coated HNSCC clusters 
after 1  h (Figure  5A, upper row) accompanied by raised IFN-
γ and TNFα medium levels (24 h PP + 1 μg/ml Cetmab + 4 h 
HNSCC cells, Figure 5D). Otherwise, the cytokine secretions of 
PP-inhibited NK cells against non-coated HNSCC cell clusters 
(without cetuximab) revealed significantly degraded IFN-γ and 
TNFα concentrations analyzed in medium supernatants [24 h PP 
(high sMICA), Figure 5D].
In addition, phenotypical analysis of relevant effector and tar-
get cell parameters were analyzed before co-cultivations. HNSCC 
cells revealed high HER1 and CD9 expression levels (not shown) 
and low-to-moderate MICA levels on the target cell clusters 
(Figure 5B). Otherwise, treated NK cells with corresponding PP 
(high sMICA, 24 h) showed a decreased NKG2D surface expres-
sion as detected by FCM analysis, while CD16 surface expression 
was unaffected (Figure 5C). In this context, sMICA and TGF-β1 
accumulated time-dependently in the cell culture medium as 
summarized in Figure  1F analyzed for different time periods 
(0–2 up to 11–14 days).
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Analysis of tumor-infiltration assays were also performed 
with PP-treated (high sMICA) NK cells co-cultured (24 h, 37°C, 
5% CO2) against non-coated HNSCC tumor spheroids. As moni-
tored for one spheroid by time-lapse imaging, effector-to-target 
cell interactions and tumor infiltrations of NK cells were strongly 
abolished and resulted in a lack of recognition of the HNSCC 
spheroid by non-functional NK cells, even though they were in 
close proximity to the spheroids (24 h, Video S1 in Supplementary 
Material). However, the PP-mediated inhibition of NK cell func-
tions was also clearly restored by cetuximab-coated HNSCC 
spheroids (1 μg/ml cetuximab) via multiple effector-target inter-
actions exemplarily shown for one representative overlay photo-
graph (Figure 6B, right overlay plot containing yellow regions) 
generated by 2D CFM. Similarly, 3D fluorescence microscopy 
allowed visualization of the reconstituted specific tumor infiltra-
tions by PP-treated (high sMICA) NK cells via putative ADCC 
in HNSCC tumor spheroids over 24 h in the presence of 1 μg/
ml cetuximab (green-yellow areas, Figure  6C). Moreover, the 
medium supernatants of those incubated samples (PP-cultured 
NK cells and cetuximab-coated HNSCC tumor spheroids) 
revealed significantly increased IFN-γ and TNFα secretion levels 
(24 h PP + 1 μg/ml Cetmab + 24 h HNSCC tumor spheroids, 
Figure  5D). However, the tumor infiltration [CD45+ NK cells 
(green signals), Figure 6D] and cytokine release [24 h PP (high 
sMICA), Figure 5D] of same PP-inhibited NK cells were strongly 
reduced in 24 h-incubated samples in absence of cetuximab and 
consequently non-coated HNSCC tumor spheroids.
DiscUssiOn
Dysfunctional tumor surveillance in HNSCC patients is further 
hampered by tumor immune escape mechanisms, which may 
induce dysregulation of immunocompetent cell profiles. In con-
trast to literature reports describing decreased NK cell numbers 
in HNSCC MNCs (54), we did not observe marked alterations in 
total NK cells among the total lymphocytes in our cohort of five 
relapsed HNSCC patients not currently in treatment. Previously, 
we demonstrated disbalances in NK cell subpopulations in 55 
patients with initial and relapsed HNSCC (22). However, the 
immunoregulatory NK cell population responsible for stimula-
tion of immature DCs by TNFα and IFN-γ secretion (5, 55) was 
significantly decreased in comparison with age-matched healthy 
individuals. Accordingly, Wulff et al. reported reduced regulatory 
NK cells in many HNSCC patients at different tumor stages (56). 
We detected higher levels of cytotoxic NK cell subpopulations 
compared to HCs, which may reflect suppressed cytotoxic 
interactions against HNSCC cells and limited tumor-infiltration 
capacities of these inhibited NK cell subsets. Additionally, we 
demonstrated that alterations in NK cell subtypes in our HNSCC 
patients were accompanied by disrupted TNFα and IFN-γ secre-
tion. Enhanced sMICA and TGF-β1 plasma levels in HNSCC 
patients also correlated strongly with NKG2D-dependent dys-
function of patient NK cells, resulting in suppressed killing activ-
ity against HNSCC cells and decreased NK cell viability during 
cytotoxic effector-target interactions. In accordance, Bose et al. 
described marked alterations in the Th1/Th2 cytokine ratios and 
significantly increased suppressor regulatory T cells in cultured 
MNCs from HNSCC patients resulted in decreased cytotoxic-
ity of HNSCC effector cells (54). According to our cytotoxicity 
experiments, high sMICA/TGF-β1 levels derived from HNSCC 
PP also contribute to diminished effector cell stability. This was 
also confirmed by Rossi et al. via correlation between impaired 
NK cell viability, effector cell cytotoxicity and decreased NKG2D 
and NKp46 surface expression (57). Increased NK cell suscepti-
bility also reflects the ability of the tumor to release apoptosis-
promoting factors (programmed death receptor ligand, PDL-1), 
which can abolish several effector cell functions within the tumor 
microenvironment as detected on PD-1+ NK cells in cancer 
patients (58, 59).
We translated an activation protocol from a previous phase I/II 
trial (Clin-Gov-No-NCT01386619), which described stimulation 
of allogeneic NK cells (1000 IU/ml IL-2) with resultant increased 
distribution of NK cell subsets and high NCR expression levels 
(11), to NK cells isolated from our HNSCC patients. After IL-2 
stimulation, the activated patient NK cells revealed improved 
distribution of increased immunoregulatory NK cells (CD56bright/
CD16dim&neg), enhanced TNFα and IFN-γ secretion and up-
regulated NKG2D expression levels that resulted in enhanced 
cytotoxicity against associated HNSCC cells. Increased expres-
sion of CD56 was coincident with higher levels of NCRs as was 
also detected in other studies, suggesting that tumor-infiltrating 
NK cells were activated effector cells, but characterized by poor 
functionality (39, 60, 61). Indeed, our incubations (24 h) of acti-
vated NK cells with sMICA analogs or PP containing increased 
sMICA resulted in decreased NKG2D expression followed by 
impaired NKG2D-dependent killing activity against associated 
HNSCC cells. However, NK cell viability and expression levels of 
CD16, pro-apoptotic FasL and TRAIL receptors as well as for the 
activation marker CD57 were not affected by sMICA. In contrast, 
the significantly decreased levels of FasL on cultured HNSCC 
MNC NK cells shown by Bose et al. might be due to marked up-
regulation of suppressor regulatory T cells followed by enhanced 
TGF-β1 secretion levels (54).
Our observations regarding inhibited cytotoxic functions 
of sMICA-treated NK cells due to suppressed HNSCC tumor 
infiltration indicate suppressed migratory capacity of NK cells 
toward HNSCC tumors as detected by transmitted time-lapse 
imaging (Video S1 in Supplementary Material). This is one of 
the numerous effector cell functionalities, impairment of which 
can result in TIEM allowing unhindered tumor growth. NKG2D 
is an activating receptor for NK, NKT, CD8+, and γδ+ T effector 
cells, and down-regulation of NKG2D in HNSCC patients seems 
to be a crucial mechanism of immune evasion. Soluble NKG2D 
ligands (NKG2DL) in association with growth factors, such as 
TGF-β1, released from mesothelioma cell-generated exosomes 
were described to potentiate the down-modulation of NKG2D 
surface expression on activated NK cells (62). Indeed, we 
observed significant correlations between time-dependent high 
sMICA and TGF-β1 secretion levels and increased HNSCC cell 
growth of our tumor clusters or spheroids, which also resulted 
in disrupted NKG2D-mediated immunosurveillance of blocked 
patient NK cells as shown previously in our HNSCC patient 
study (22). However, the negative impact of increased TGF-β1 
levels detected in these HNSCC patients could be inhibited by 
FigUre 6 | reconstitution of nK cell-dependent tumor infiltration by cetuximab. Tumor recognition and infiltration of sMICA-affected NK cells in absence or 
presence of cetuximab (1 μg/ml) were analyzed by co-culturing (24 h, 37°C, 5% CO2) of corresponding patient NK cells, plasma (high sMICA) and HNSCC tumor 
spheroids derived from HNSCC patient tumors (n = 5). Activated NK cells were pre-incubated (24 h) with corresponding patient plasma containing high sMICA 
(PP: > 500 pg/ml; diluted 1:2 with X-VIVO™10) and co-incubated (24 h) with primary HNSCC spheroids (time of cultivation: 11–14 days) in the presence of 1 μg/ml 
cetuximab. CD45 (green) for PP-treated patient NK cells were identified by staining with FITC-conjugated mAb, whereas tumor spheroids were labeled with 
anti-HER2 PE-conjugated mABs (a). Tumor-infiltrating NK cells were illustrated by overlay plots (CFM). Exactly the same orientation of CD45+ NK cells (green) and 
HER2+ tumor spheroids (red) showed a positive, overlapping signal in yellow [see black arrows (B)] for ADCC-related effector-target cell interactions, whereas single 
positive, HNSCC cells (CD45−/HER2+) are shown as red signals and single positive NK cells are depicted by green signals in the corresponding photographs (a). 3D 
fluorescence microscopy visualized tumor-infiltrating patient NK cells (green-yellow areas) in corresponding HNSCC tumor spheroids in the presence (c) and 
absence (D) of 1 μg/ml cetuximab. DAPI [blue signals (a,c,D)] was used to stain DNA from methanol-fixed effector and target cells for analyses of the nuclear 
morphology.
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neutralization antibodies against this immunosuppressive factor, 
indicating that TGF-β1 seemed to potentiate the sMICA-induced 
decrease of patient NK cell cytotoxicity and diminished NKG2D 
expression. According to our results, others have demonstrated 
restored NKG2D expression levels on NK and CD8+ T cells after 
tumor resection in glioma patients, which was accompanied 
by enhanced killing activities of those effector cells against 
NKG2DL-positive tumor targets (63). Interestingly, NKG2D was 
markedly down-regulated on activated CD8+ T cells but only if 
CD4+ T cells and NKG2DLs, such as soluble MICB, were present 
(64). This observation supports the hypothesis that soluble 
NKG2DLs played a secondary role and the down-regulation of 
NKG2D was primarily caused by tumor-derived TGF-β1 (63). 
The immunosuppressive tumor environment was responsible 
for the high diversity of antigen presentation patterns in stroma-
infiltrating NK cells and tumor-infiltrating NK cells. The effector 
cells showed lower CD56 levels and higher CD16 expression dur-
ing cytotoxic interactions with breast cancer cells and resulted in 
altered NK cell phenotypes with decreased functional capacities 
(65). In accordance with this report, we demonstrate stable CD16 
expression levels, which were not affected by sMICA analogs or 
HNSCC plasma containing high amounts of sMICA and TGF-β1.
NK cell subsets have a stimulating Fc receptor for binding 
IgG (Fcγ RIIIa), which induces ADCC and may trigger TNFα 
and IFN-γ secretion to finally recognize and kill antibody-coated 
targets (66). Since several ErbB family members, including HER1 
(EGFR), HER2 and HER3, seem to be strong predictors for the 
outcome of HNSCC (67), we stained different tumor samples 
post-surgery from corresponding relapsed patients for HER1/2 
and collected PB for NK cell separation as well as blood plasma 
for quantification of sMICA and TGF-β1. The chimeric (human-
murine) IgG1 cetuximab directly affects HER1-positive tumor 
cells by activation immunocompetent cells (66). Therefore, we 
assessed our sMICA-affected NK cells regarding to cytotoxicity 
and tumor infiltrations. We found improved killing activity via 
ADCC for sMICA-inhibited NK cells against cetuximab-coated 
HNSCC cells. Additionally, enhanced cytokine (TNFα and IFN-
γ) release was observed compared to low cell lysis of the same 
effector cells co-cultured with untreated tumor cells. Negative 
effects of sMICA and TGF-β1 on NK cell cytotoxicity were 
overcome by cetuximab and correlated well with high IFN-γ 
and TNFα secretion levels described previously in HNSCC 
and other cancers (53, 68). In this context, it was reported that 
cetuximab-induced NK cells are able to activate DC maturation 
markers and antigen presentation machinery via IFN-γ secre-
tion, thus allowing initiation of adaptive immune responses by 
NK cell stimulated DC maturation (69). We demonstrated that 
combining cetuximab with IL-2 (1000 IU/ml) re-established NK 
cell cytotoxicity and reconstituted TNFα and IFN-γ secretion. 
This is in agreement with other reports that described increased 
ADCC activity and cytokine release in the presence of cetuximab 
and several cytokines (IL-2, IL-12, IL-15, and IL-21) compared to 
cetuximab-mediated ADCC in absence of these cytokines (53, 65, 
68). Prospective studies should clarify how to improve the cetuxi-
mab effect combined with pro-inflammatory cytokines, especially 
IL-2. Interestingly, it was demonstrated that ADCC- and IL-2-
activated NK cells were less susceptible to immunosuppression 
by chemotherapy or other immunosuppressive drugs, especially 
mycophenolate mofetil (MMF), than non-stimulated NK cells in 
cancer patients (68, 70).
To investigate the potency of cetuximab on cytotoxic function-
alities of sMICA-inhibited NK cells, we generated HER1-positive 
tumor spheroids to simulate the in vivo tumor microenvironment. 
This enabled us to analyze the restoration of tumor-infiltrating 
capability of NK cells with down-regulated NKG2D expression 
levels in a well-defined system. Tumor spheroids were utilized 
to monitor specific migratory capability and tumor chemoat-
traction of effector cells, especially NK cells, over well-defined 
time periods (71). However, only few reports describe the effec-
tor cell-mediated immunosurveillance toward tumor spheroids. 
Inactivation of NK cells by clustered Ewing’s sarcoma cells and 
cytotoxicity of γδ+ T cells against pediatric liver tumor spheroids 
was demonstrated (72, 73). In our tumor models, we were able to 
assess the cetuximab-mediated tumor infiltration from sMICA-
inhibited NK cells toward corresponding primary HNSCC cell 
clusters and tumor spheroids that expressed high levels of HER1 
and HER2. HNSCC spheroids expressed only low-to-moderate 
levels of membrane-bound MICA, but sMICA and TGF-β1 
release steadily increased in supernatants of cultured HNSCC 
tumor spheroids and reached saturation levels after a few days 
of cultivation. The accumulation of immunosuppressive factors 
in HNSCC spheroid supernatants supported the assumption 
that NKG2D-mediated cytotoxicity of co-cultured patient NK 
cells was diminished, which corroborates the negative effect 
toward NK cell-mediated immunosurveillance by these tumor 
spheroids as described previously (71). Importantly, we detected 
early effector-to-target interactions displayed in small HNSCC 
tumor cell clusters during the first hours of co-cultivation in the 
presence of cetuximab. Furthermore, we successfully demon-
strated cetuximab-mediated tumor infiltrations and increased 
TNFα and IFN-γ secretions of sMICA-inhibited NK cells in 
associated HNSCC spheroids using 2D- and 3D-microscopy 
techniques. This supported results from monolayer cultures of 
different effector-to-target cell ratios co-incubated for previous 
cytotoxicity assays. Correspondingly, others evaluated the direct 
localization of fluorescently stained therapeutic antibody, cetux-
imab-IRDye800CW, in histologic sections with tonsil, tongue, 
and cutaneous squamous cell carcinoma (SCC) by fluorescence 
immunohistochemistry (74). Interestingly, the heterogeneous 
composition and tumor architecture in short-term culture of 
HNSCC tumor slices demonstrated a high diversity of individual 
responses to cetuximab, but the absence of any effector cell subset 
(75). It was recently suggested that drug resistance to anti-EGFR 
therapies in HNSCC is not affected by the hypoxic tumor 
microenvironment within the investigated tumors (76). Indeed, 
the inhibition of EGFR via cetuximab reduces angiogenesis via 
hypoxia-inducible factor-1α and Notch1 in HNSCC (77).
cOnclUsiOn
In conclusion, our current results emphasize that cetuximab is 
able to neutralize negative effects of TIEMs. This was shown in 
a corresponding effector-target system of patient NK cells, PP 
containing immunosuppressive factors (sMICA and TGF-β1), 
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and associated HNSCC tumors/tumor cells as targets. This is of 
clinical relevance as the shedding of soluble NKG2DLs combined 
with secretion of immunosuppressive cytokines may promote 
tumor progression and is predictive for a negative prognosis in 
tumor patients (78).
In summary, observations of our clinical phase I/II haploiden-
tical NK cell study for adaptive immunotherapy (Clin-Gov-No-
NCT01386619) (47, 79, 80) and our current results indicate that 
allogeneic NK cells in combination with tumor antigen-specific 
mAbs, especially cetuximab, might be an innovative approach 
to circumvent TIEM-derived limitations against patient NK 
cells. Therefore, it is necessary to monitor overexpressed tumor 
antigens, such as HER1, and immunosuppressive ligands and 
the polymorphic Fcγ receptor IIIa to regenerate the tumoricidal 
properties of NK cells for improved therapeutic benefit.
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Figure s1 | gating strategy. Flow cytometry-based cytotoxicity assay of NK 
cells against singularized HNSCC cells. NK and HNSCC cells were stained with 
CD9 FITC, CD56 PC7, and CD45 KO mAbs. 7-AAD (7-amino-actinomycin D) 
was used to discriminate non-viable cells in FCM. Blue: CD45+ NK cells; red: 
CD9+ HNSSC cells; and grey: 7-AAD+ effector and target cells. Dot plot areas 
were defined by the analysis of mono-cultured NK and HNSCC cells incubated 
for the identical time periods. Dot plot (WBC/MNC) displays an overview of all 
scatter events properties, and shows differentiations to non-specifically stained 
debris by low forward scatter signals. Plot (CAL) illustrates the events of the 
region “beads” along the time course to calibrate the events for “cells/μl” and 
detect even sample flow. Region (Target cells) is defined to include viable CD9+ 
HNSCC cells, and region (Effector cells) is defined to include all CD45+ NK 
cells. Plot (“Cell clusters”) represents the viable effector-target–cell interactions. 
Plot (“Viability”) is defined as a region to exclude the 7-AAD+ cells. These 
7-AAD+ cells are not further presented in the following dot plots by using the 
characteristic signal when representing the 7-AAD fluorescence against the side 
scatter (SSC) properties.
Video s1 | Time-lapse imaging of PP (high sMica and TgF-beta1 
levels)-treated nK cells against corresponding hnscc tumor spheroids 
over a time period of 24 h. These NK cells (smaller rounded effector cells) 
isolated from the same HNSCC patient showed a decreased tumor recognition 
against associated tumor spheroids via reduced migratory capability and a 
decreased cytotoxicity.
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